End-of-day quote
Shenzhen S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
35.1
CNY
|
-1.68%
|
|
-12.71%
|
-42.56%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
79,456
|
236,656
|
199,360
|
140,528
|
146,664
|
84,022
|
-
|
-
|
Enterprise Value (EV)
1 |
80,690
|
238,093
|
195,858
|
139,911
|
143,334
|
75,752
|
69,633
|
61,193
|
P/E ratio
|
33.6
x
|
71.7
x
|
19.5
x
|
18.6
x
|
18.2
x
|
9.27
x
|
6.74
x
|
7.33
x
|
Yield
|
1.01%
|
0.34%
|
0.48%
|
0.57%
|
1.31%
|
1.91%
|
1.94%
|
2.28%
|
Capitalization / Revenue
|
7.5
x
|
15.6
x
|
6.5
x
|
3.67
x
|
2.77
x
|
1.47
x
|
1.26
x
|
1.33
x
|
EV / Revenue
|
7.62
x
|
15.7
x
|
6.39
x
|
3.66
x
|
2.71
x
|
1.33
x
|
1.04
x
|
0.97
x
|
EV / EBITDA
|
27.7
x
|
59.1
x
|
15.8
x
|
15.4
x
|
14.8
x
|
6.65
x
|
5.16
x
|
4.36
x
|
EV / FCF
|
102
x
|
89.2
x
|
29.8
x
|
261
x
|
17.8
x
|
38.1
x
|
8.95
x
|
5.07
x
|
FCF Yield
|
0.98%
|
1.12%
|
3.36%
|
0.38%
|
5.6%
|
2.62%
|
11.2%
|
19.7%
|
Price to Book
|
13.8
x
|
28.7
x
|
11.3
x
|
5.8
x
|
4.66
x
|
2.11
x
|
1.61
x
|
1.38
x
|
Nbr of stocks (in thousands)
|
2,400,000
|
2,400,000
|
2,400,000
|
2,400,000
|
2,400,000
|
2,393,790
|
-
|
-
|
Reference price
2 |
33.11
|
98.61
|
83.07
|
58.55
|
61.11
|
35.10
|
35.10
|
35.10
|
Announcement Date
|
2/27/20
|
2/21/21
|
2/8/22
|
3/20/23
|
4/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
10,587
|
15,190
|
30,652
|
38,264
|
52,918
|
57,093
|
66,731
|
63,360
|
EBITDA
1 |
2,910
|
4,027
|
12,394
|
9,079
|
9,700
|
11,397
|
13,506
|
14,030
|
EBIT
1 |
2,814
|
3,895
|
12,000
|
8,758
|
9,373
|
10,520
|
14,329
|
13,346
|
Operating Margin
|
26.57%
|
25.64%
|
39.15%
|
22.89%
|
17.71%
|
18.43%
|
21.47%
|
21.06%
|
Earnings before Tax (EBT)
1 |
2,765
|
3,854
|
11,931
|
8,718
|
9,342
|
10,679
|
14,661
|
15,570
|
Net income
1 |
2,366
|
3,301
|
10,209
|
7,539
|
8,070
|
9,200
|
12,785
|
12,095
|
Net margin
|
22.35%
|
21.73%
|
33.3%
|
19.7%
|
15.25%
|
16.11%
|
19.16%
|
19.09%
|
EPS
2 |
0.9860
|
1.376
|
4.254
|
3.141
|
3.362
|
3.785
|
5.208
|
4.786
|
Free Cash Flow
1 |
794.3
|
2,670
|
6,576
|
536.6
|
8,030
|
1,986
|
7,784
|
12,078
|
FCF margin
|
7.5%
|
17.58%
|
21.45%
|
1.4%
|
15.18%
|
3.48%
|
11.66%
|
19.06%
|
FCF Conversion (EBITDA)
|
27.29%
|
66.31%
|
53.06%
|
5.91%
|
82.79%
|
17.43%
|
57.63%
|
86.09%
|
FCF Conversion (Net income)
|
33.56%
|
80.87%
|
64.41%
|
7.12%
|
99.51%
|
21.59%
|
60.88%
|
99.86%
|
Dividend per Share
2 |
0.3333
|
0.3333
|
0.4000
|
0.3333
|
0.8000
|
0.6698
|
0.6796
|
0.7990
|
Announcement Date
|
2/27/20
|
2/21/21
|
2/8/22
|
3/20/23
|
4/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
8,824
|
8,841
|
9,513
|
9,470
|
10,441
|
11,173
|
13,273
|
14,826
|
13,646
|
11,396
|
12,505
|
15,632
|
15,632
|
11,341
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2,482
|
3,723
|
3,723
|
-
|
-
|
EBIT
1 |
-
|
2,126
|
2,269
|
2,105
|
2,142
|
2,242
|
2,397
|
2,711
|
2,668
|
1,738
|
1,737
|
2,730
|
2,921
|
3,089
|
2,292
|
-
|
Operating Margin
|
-
|
24.09%
|
25.67%
|
22.12%
|
22.62%
|
21.47%
|
21.45%
|
20.43%
|
18%
|
12.73%
|
15.24%
|
21.83%
|
18.69%
|
19.76%
|
20.21%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
2,090
|
2,129
|
2,235
|
2,392
|
2,570
|
2,657
|
1,723
|
1,734
|
2,403
|
3,604
|
3,604
|
-
|
-
|
Net income
1 |
5,491
|
-
|
-
|
1,806
|
1,878
|
1,932
|
2,032
|
2,228
|
2,270
|
1,540
|
1,458
|
2,078
|
3,117
|
3,117
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
18.99%
|
19.83%
|
18.5%
|
18.19%
|
16.79%
|
15.31%
|
11.28%
|
12.79%
|
16.62%
|
19.94%
|
19.94%
|
-
|
-
|
EPS
2 |
-
|
0.7533
|
-
|
0.7533
|
0.7800
|
0.8067
|
0.8467
|
0.9283
|
0.9400
|
0.6400
|
0.6090
|
0.8700
|
0.9300
|
1.180
|
0.8400
|
-
|
Dividend per Share
2 |
-
|
0.4000
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.1148
|
0.1148
|
0.1148
|
0.1320
|
0.1320
|
Announcement Date
|
8/29/21
|
2/8/22
|
4/27/22
|
8/29/22
|
10/27/22
|
3/20/23
|
4/19/23
|
8/28/23
|
10/26/23
|
4/22/24
|
4/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
1,234
|
1,437
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
3,502
|
617
|
3,330
|
8,270
|
14,389
|
22,829
|
Leverage (Debt/EBITDA)
|
0.424
x
|
0.3568
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
794
|
2,670
|
6,576
|
537
|
8,030
|
1,986
|
7,784
|
12,079
|
ROE (net income / shareholders' equity)
|
47.7%
|
46.3%
|
78%
|
36.1%
|
29.1%
|
26.3%
|
25.8%
|
20.9%
|
ROA (Net income/ Total Assets)
|
26.7%
|
25.2%
|
45.1%
|
-
|
-
|
17.6%
|
16.7%
|
13.5%
|
Assets
1 |
8,876
|
13,079
|
22,648
|
-
|
-
|
52,272
|
76,480
|
89,595
|
Book Value Per Share
2 |
2.390
|
3.440
|
7.360
|
10.10
|
13.10
|
16.70
|
21.80
|
25.40
|
Cash Flow per Share
2 |
0.5700
|
1.460
|
3.540
|
0.8300
|
3.750
|
3.090
|
3.870
|
5.020
|
Capex
1 |
573
|
827
|
1,932
|
1,452
|
966
|
910
|
1,439
|
1,280
|
Capex / Sales
|
5.41%
|
5.44%
|
6.3%
|
3.8%
|
1.83%
|
1.59%
|
2.16%
|
2.02%
|
Announcement Date
|
2/27/20
|
2/21/21
|
2/8/22
|
3/20/23
|
4/22/24
|
-
|
-
|
-
|
Last Close Price
35.1
CNY Average target price
62.47
CNY Spread / Average Target +77.97% Consensus |
1st Jan change
|
Capi.
|
---|
| -42.56% | 11.61B | | -3.93% | 86.16B | | +2.76% | 40.17B | | -16.48% | 31.47B | | +54.56% | 25.24B | | -13.58% | 15.82B | | -9.12% | 11.96B | | +5.54% | 8.84B | | -2.22% | 7.93B | | +1.55% | 7.68B |
Biopharmaceuticals
|